Cardiogenic shock with non-ST- segment elevation myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded coronaries for Cardiogenic shocK? J Am Coll Cardiol. 2000;36:1091 6. 596. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779 89. 597. Cheng JM, den Uil CA, Hoeks SE, et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardio- genic shock: a meta-analysis of controlled trials. Eur Heart J. 2009;30:2102 8. 598. Chen EW, Canto JG, Parsons LS, et al. Relation between hospital intra- aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation. 2003; 108:951 7. 599. Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clini- cal study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock.Am Heart J. 2006;152. 469 8. 600. Seyfarth M, Sibbing D, Bauer I, et al.A randomized clinical trial to evalu- ate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52:1584 8. 601. Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consider- ation of the extent of coronary artery disease and benefits of revascular- ization. J Am Coll Cardiol. 2004;43:585 91. 602. Silva JA, Escobar A, Collins TJ, et al. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation. 1995;92:1731 6. 603. Elbarouni B, Ismaeil N, Yan RT, et al. 